Compass Therapeutics Inc. Common Stock (CMPX)
Stock · NASDAQ · Health Care
$0.86as of 10/16/2026
Price chart
Active signals
CMPX Signal Track Record
How signals performed across all stocks →What CMPX's price did in the 20 trading sessions after each past signal, compared with any 20-session window over the same period.
| Signal | Times | Median 20-session return | Higher after 20 sessions | Last signal |
|---|---|---|---|---|
| Volume Spike | 45 | 0.0% | 49% | October 1, 2026 |
| Bollinger Band Breakout | 23 | -0.5% | 48% | August 12, 2026 |
| Bollinger Band Breakdown | 21 | -0.3% | 48% | September 9, 2026 |
| 200-Day Moving Average TouchActive now | 8 | +11.2% | 75% | April 30, 2025 |
| Any 20-session window (baseline) | -0.4% | 48% |
Computed by MarketWall from daily closing prices since May 18, 2022. Returns are close-to-close and don't include dividends. Past results describe what happened before; they are not a forecast and not investment advice.
About CMPX
Compass Therapeutics, Inc., a clinical-stage oncology-focused biopharmaceutical company, develops antibody-based therapeutics for the treatment of various human diseases in the United States. The company's lead product candidate, tovecimig, is a bispecific antibody that targets delta-like ligand 4 (DLL4) and vascular endothelial growth factor A (VEGF-A), which are critical to angiogenesis and tumor vascularization. I…
- Sector
- Health Care
- Industry
- Biotechnology: Biological Products (No Diagnostic Substances)
- Employees
- 39
- Website
- www.compasstherapeutics.com/
Fundamentals
- 1-day range
- $0.8294$0.9798
- Market cap
- $358.37M
- P/E (trailing)
- —
- P/E (forward)
- -1.59
- EPS (trailing)
- $-0.31
- Dividend yield
- —
- Beta
- 1.07
- Avg. volume
- 3.81M
Forecasts
11 analyst ratings
Compass Therapeutics Inc. Common Stock Competitors
Chosen by industry and closest market cap.
- CMPXCompass Therapeutics Inc. Common Stock$0.86▼ 4.12%Market cap $358.37MP/E —$0.8294$6.88
- LXEOLexeo Therapeutics Inc. Common Stock$2.64▼ 4.35%Market cap $357.27MP/E —$2.56$10.99
- PALIPalisade Bio Inc. Common Stock$1.41▼ 8.44%Market cap $362.78MP/E —$1.32$2.86
- IPSCCentury Therapeutics Inc. Common Stock$1.37▼ 8.67%Market cap $342.67MP/E —$0.435$3.04
- FENCFennec Pharmaceuticals Inc. Common Stock$9.98▼ 3.57%Market cap $378.17MP/E —$5.65$13.25
- AGENAgenus Inc. Common Stock$6.04▼ 9.58%Market cap $335.19MP/E 3.19$2.71$10.31
- XFORX4 Pharmaceuticals Inc. Common Stock$2.59▼ 1.89%Market cap $393.31MP/E 3.24$2.43$4.83
| Symbol | Market cap | P/E ratio | Price | 1D | 52-week range |
|---|---|---|---|---|---|
| CMPX Compass Therapeutics Inc. Common Stock | $358.37M | — | $0.86 | ▼ 4.12% | $0.8294$6.88 |
| LXEO Lexeo Therapeutics Inc. Common Stock | $357.27M | — | $2.64 | ▼ 4.35% | $2.56$10.99 |
| PALI Palisade Bio Inc. Common Stock | $362.78M | — | $1.41 | ▼ 8.44% | $1.32$2.86 |
| IPSC Century Therapeutics Inc. Common Stock | $342.67M | — | $1.37 | ▼ 8.67% | $0.435$3.04 |
| FENC Fennec Pharmaceuticals Inc. Common Stock | $378.17M | — | $9.98 | ▼ 3.57% | $5.65$13.25 |
| AGEN Agenus Inc. Common Stock | $335.19M | 3.19 | $6.04 | ▼ 9.58% | $2.71$10.31 |
| XFOR X4 Pharmaceuticals Inc. Common Stock | $393.31M | 3.24 | $2.59 | ▼ 1.89% | $2.43$4.83 |
P/E shows — for peers not currently carrying a live signal of their own.
Latest news
- Curious about the stocks that are showing activity after the closing bell on Friday?ChartMill · 10/2/2026
- This Yum Brands Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For ThursdayBenzinga · 9/24/2026
- Microsoft upgraded, HubSpot initiated: Wall Street's top analyst callsYahoo · 9/23/2026
- Compass Therapeutics’ FDA Setback Raises Concerns On Wall Street — H.C. Wainwright Calls Tovecimig Filing Strategy ‘Risky’Yahoo · 9/23/2026
- Craig-Hallum Maintains Buy on Compass Therapeutics, Lowers Price Target to $8Benzinga · 9/23/2026
- Compass Therapeutics: A Promising, But Shrinking, Window Of OpportunitySeekingAlpha · 9/23/2026
- This Autoliv Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For WednesdayBenzinga · 9/23/2026
- Citizens Maintains Market Outperform on Compass Therapeutics, Lowers Price Target to $4Benzinga · 9/23/2026
Insider Activity
Insider Actions →- Neil Lerner · October 1, 2026 · Buy20.0K @ $0.92
- Neil Lerner · September 24, 2026 · Buy2.5K @ $1.14
- Jonathan Anderman · April 29, 2026 · Grant25.0K @ $1.89
- Neil Lerner · April 29, 2026 · Grant15.0K @ $1.89
Institutional Ownership
March 31, 2026
- Total shares held
- 173.56M
- Total value held
- $919.58M
- Institutional holders
- 196
- Unknown16.79M
- Unknown15.22M
- Unknown14.31M
- Unknown9.55M
- Unknown9.51M
- Unknown8.49M
- Unknown7.79M
- Unknown7.76M
- Unknown6.69M
- Unknown6.04M
See the full, filterable feed with live charts on the MarketWall dashboard.
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 26, 2026
Compass Therapeutics faces analyst downgrades after FDA setback
Compass Therapeutics is facing renewed scrutiny following an FDA setback for tovecimig, which H.C. Wainwright described as a risky filing strategy. Several firms, including Citizens, Guggenheim, and Craig-Hallum, lowered their price targets to $4 or $8 while maintaining positive ratings. The stock's RSI is near 20.7, indicating it is currently trading in oversold territory.
Compass Therapeutics faces analyst downgrades after FDA setback. Compass Therapeutics is facing renewed scrutiny following an FDA setback for tovecimig, which H.C. Wainwright described as a risky filing strategy. Several firms, including Citizens, Guggenheim, and Craig-Hallum, lowered their price targets to $4 or $8 while maintaining positive ratings. The stock's RSI is near 20.7, indicating it is currently trading in oversold territory.